Research Report on China's Biopharmaceutical Industry, 2009

March 2009 | 80 pages | ID: RBF32139098EN
China Research and Intelligence Co., Ltd.

Abstracts

In 2008, the market size of China’s biopharmaceutical industry was about 70 billion Yuan (about 10 billion US Dollars), whose growth rate passed the whole market size of China’s medicine market and also above three sub-sectors including chemical medicine materials, chemical medicine dose and traditional Chinese prepared medicines. Under the circumstances of global economic depression, however, China’s biopharmaceutical industry shows a good momentum of development.

The author spent two months to interview a large number of China’s biopharmaceutical manufacturers and wrote this report depending on abundant second-hand information. The author is not only familiar with China’s biopharmaceutical industry but also proficient in the means of market research.

More information can be obtained as follows:
- Market size and development of China’s biopharmaceutical industry
- Technologies of China’s biopharmaceutical industry
- Main local enterprises’ operations of biopharmaceutical industry
- Main foreign funded enterprises’ operations of China’s biopharmaceutical industry
- Competition of China’s biopharmaceutical industry
- Development of sub-sectors of China’s biopharmaceutical industry
- Development trends of China’s biopharmaceutical industry

Contents

1 GENERAL SITUATION OF CHINA’S BIOPHARMACEUTICAL INDUSTRY

1.1 Overview on the Biopharmaceutical Industry
  1.1.1 Definition of Biopharmaceuticals
  1.1.2 Development History of China’s Biopharmaceuticals
  1.1.3 Development Environment
1.2 Applications of Biopharmaceutical
  1.2.1 Application fields of Biopharmaceuticals
  1.2.2 Features of the Biopharmaceutical Industry
1.3 Development State of China’s Biopharmaceutical Industry

2 MARKET SITUATION OF THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

2.1 Characteristics of the Global Biopharmaceutical Industry
  2.1.1 Development Situation
  2.1.2 Market Size of the Biological Medicine industry
  2.1.3 Trends of Product Concentration of the Biological Medicine Industry
  2.1.4 Bright Futures of the Biological Medicine and Natural Medicine
  2.1.5 Climaxes of Mergers and Acquisition
  2.1.6 Government officials focus on the Development of the Biological Industry
2.2 General Competitive Situation of Global Biological Medicines
  2.2.1 Industrialization of Biological Medicines
  2.2.2 Uncertainty from Long Return Cycle
2.3 Asian Competitive Situation of the Global Biopharmaceutical Industry
  2.3.1 Analysis on Biomedical Outsourcing
  2.3.2 Market and Policy Environment Comparison between China and India
  2.3.3 Evaluation on China
  2.3.4 Assessment on India
2.4 Development of the Biopharmaceutical Industry in Main Countries
  2.4.1 America
  2.4.2 Europe
  2.4.3 India
2.5 Analysis of the Distribution of Multinational Biopharmaceutical Enterprises in China
  2.5.1 Significance Analysis
  2.5.2 Present Situation Analysis

3 MAIN PRODUCTS ANALYSIS OF CHINESE BIOPHARMACEUTICAL INDUSTRY

3.1 Blood Products
  3.1.1 Present State of Chinese Blood Product Industry
  3.1.2 Product Structures
  3.1.3 Development Perspectives
3.2 Vaccine Products
  3.2.1 Present State
  3.2.2 Development Perspectives
3.3 Diagnostic Reagents
  3.3.1 Present State
  3.3.2 Development Perspectives
3.4 Recombinant Drugs
  3.4.1 Present State
  3.4.2 Technical Gaps
3.5 Recombinant Proteins
  3.5.1 Market Analysis
  3.5.2 Development Perspectives
3.6 Monoclonal Antibody
3.7 Interferon IFN
  3.7.1 Present State
  3.7.2 Development Perspectives
3.8 Bio-genetic Engineering
3.9 Human Growth Hormone
3.10 Insulin
3.11 Developing Biopharmaceuticals
  3.11.1 Tumor Vaccine
  3.11.2 Polypeptide Drugs
  3.11.3 Extrinsic Diagnostic Tests

4 OPERATIONS OF BIOLOGICAL PRODUCTS AND BIOCHEMICAL’S MANUFACTURERS IN CHINA, 2007-2008

4.1 Major Economic Indicators of the Industry, 2007-2008
4.2 Productions and Sales of the whole nation and provinces, 2007-2008
4.3 Assets of the Industry, 2007-2008
4.4 Profitability in the nation and provinces, 2007-2008

5 COMPETITION OF CHINA’S BIOPHARMACEUTICAL INDUSTRY

5.1 Competition Situation of the Medical Industry
  5.1.1 Barrier Analysis
  5.1.2 Concentration of the Industry
  5.1.3 Competing methods
  5.1.4 Competitions in Sub-industries
5.2 SWOT Analysis on China’s Biopharmaceutical Industry
  5.2.1 Strength
  5.2.2 Weaknesses
  5.2.3 Opportunities
  5.2.4 Threats

6 MAIN FOREIGN FUNDED BIOPHARMACEUTICAL ENTERPRISES IN CHINA

6.1 GlaxoSmithKline (China) Investment Co., Ltd
  6.1.1 Company Profile
  6.1.2 Operations of GlaxoSmithKline (China) Investment Co., Ltd in Shanghai
  6.1.3 Development Perspectives in China
6.2 Sanofi Pasteur
  6.2.1 Company Profile
  6.2.2 Operations of Sanofi Pasteur in Shenzhen
  6.2.3 Development Perspectives in China
6.3 U.S.A. Inverness Medical, Inc.
  6.3.1 Company Profile
  6.3.2 Operations of ABON Biopharm (Hangzhou) Co., Ltd
  6.3.3 Development Perspectives in China
6.4 Kirin Kunpeng (China) Bio-pharmaceutical Co., Ltd
  6.4.1 Company Profile
  6.4.2 Operations of Kirin Kunpeng (China) Bio-pharmaceutical Co., Ltd
  6.4.3 Development Perspectives in China
6.5 InTec PRODUCTS, INC.,
6.6 Others

7 LOCAL COMPANIES OF THE BIOPHARMACEUTICAL INDUSTRY

7.1 Hualan Biological Engineering Co., Ltd
  7.1.1 Company Profile
  7.1.2 Operations
  7.1.3 Main Biopharmaceutical Products
  7.1.4 Development Strategies
7.2 Beijing Tiantan Biological Products Co., Ltd
  7.2.1 Company Profile
  7.2.2 Operations
  7.2.3 Main Biopharmaceutical Products
  7.2.4 Development Strategies
7.3 Shanghai Institute of Biological Products
  7.3.1 Company Profile
  7.3.2 Operations
  7.3.3 Main Biopharmaceutical Products
  7.3.4 Development Strategies
7.4 Shanghai Kekua Boi-engineering CO., LTD
7.5 DaAn Gene Co., Ltd
7.6 Beijing SL Pharmaceutical Co., Ltd.
7.7 Shenzhen Neptunus Bioengineering CO., LTD
7.8 Chengdu Ronsen Co., LTD
7.9 Shanghai Laishi Blood products CO., LTD
7.10 Shandong Taibang Pharmaceutical Co., LTD
7.11 Sichuan Yuanda Shuyang Pharmaceutical Co., LTD
7.12 Guiyang Qinfeng Pharmaceutical Co., LTD

8 DEVELOPMENT PERSPECTIVES OF CHINA’S BIOPHARMACEUTICAL INDUSTRY

8.1 General Perspectives
  8.1.1 Huge Market Potential
  8.1.2 Industry Shift to China
8.2 Perspectives of Main Products in China’s Biological Medicine Industry
  8.2.1 Human Serum Albumin
  8.2.2 Hyperimmune
  8.2.3 Specific Immunogkobukin
  8.2.4 Protection Hepatitis B Vaccine
  8.2.5 Influenza Vaccine
  8.2.6 Rabies Vaccine
  8.2.7 AIDS Vaccine
  8.2.8 Therapeutic Vaccine
  8.2.9 Interferon
  8.2.10 Insulin and Its Similarities
  8.2.11 Recombinant Human Erythropoietin
  8.2.12 Human Granulocyte Colony Stimulating Factor
  8.2.13 Interleukin
  8.2.14 Recombinant human Endostatin

Selected Charts

SELECTED CHARTS

Chart Market Sizes of China’s Biopharmaceutical Industry, 2004-2008
Chart Main Product Categories of China’s Biopharmaceutical Industry
Chart Top Ten Enterprises of China’s Biopharmaceutical Industry, 2007-2008
Chart Market sizes of China’s Blood Products, 2004-2008
Chart Market sizes of China’s Vaccine, 2004-2008
Chart Operations of Hualan Biological Engineering Co., Ltd, 2007-2008